HOME > TOP STORIES
TOP STORIES
-
REGULATORY Report Systems for Improper Drug Promotion Little-Known among Pharmacists: MHLW Study
June 16, 2021
-
REGULATORY Honebuto Text to Add Line for “Transparency and Predictability” of Drug Pricing System
June 16, 2021
-
BUSINESS Daiichi Sankyo Drops Nafamostat Development for COVID-19
June 16, 2021
-
BUSINESS Shipment Curbs of 3,000-Plus Products Taking a Toll on Wholesalers as Generic Woes Continue
June 15, 2021
-
ORGANIZATION Saitama-Based Hospital Group Introduces Formulary in 18 Therapeutic Areas, Aims to Spread Know-How in Region
June 15, 2021
-
ORGANIZATION FPMAJ Drug Price Report Rebuts Issues Raised over Cost-Plus Method, PMP and More
June 14, 2021
-
BUSINESS Japan Approves 1st Oncolytic Virus, Delytact, for Malignant Glioma
June 14, 2021
-
REGULATORY LDP Flags 80% Generic Target for All Prefectures: Honebuto Debate
June 11, 2021
-
BUSINESS Eisai CEO Says Aducanumab Price Tag Reflects Its Value, 1 Million Patients Estimated in Japan
June 10, 2021
-
REGULATORY Govt Unveils Draft Honebuto Paper for 2021, Cabinet OK Expected after Party Tweaks
June 10, 2021
-
BUSINESS Aducanumab Gets Accelerated OK, Expert Says FDA Verdict Would Affect Japan Review Too
June 9, 2021
-
REGULATORY Japan Aims for 80% Generic Share in All Prefectures by FY2023-End: Honebuto Draft
June 9, 2021
-
BUSINESS Japan Drug Makers Derive Near-60% of FY2020 Sales Overseas as Home Market Falters: Tally
June 8, 2021
-
BUSINESS FDA Approves Aducanumab, 1st Disease-Modifying Therapy for Alzheimer’s
June 8, 2021
-
BUSINESS Bristol Myers, Other Pharma Players Moving to Join Workplace Vaccination Campaign
June 7, 2021
-
BUSINESS Kobayashi Kako’s 116-Day Suspension Over, but No Timeline for Resumption
June 7, 2021
-
ACADEMIA As Aducanumab Decision Nears, Health Economist Stresses Need for Broad Value Evaluation, Target Patient Criteria
June 4, 2021
-
BUSINESS MSD Japan Spins Off Organon Women’s Health Biz, Ryota Sakurai Takes Helm
June 4, 2021
-
BUSINESS Astellas Plans to Cut 450 Jobs via Voluntary Redundancy Program
June 4, 2021
-
REGULATORY Japan to Establish Ecosystem to Deliver Innovative Drugs: Draft Growth Strategy
June 3, 2021
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
